1,445 Spam-Free Article(s) Found
Sort:
Like
Filter:
All
Symbol Name Last Close Mkt Cap DailyStocks'
Rating
Our DailyStocks’ Rating System is a proprietary algorithm that combines the vote of the investor community and legendary trader Richard Dennis’ Turtle Trader System and the System Rules of the Turtle Traders Each day, we generate Buy, Sell, Uptrend or Downtrend signals for 3000 Stocks in the U.S. Markets.
Vote Now!
Thursday’s Close
NVS Novartis AG $85.13 $197.65B N/A
Article Searches
Better Buy: Philip Morris International Inc. vs. Anheuser-Busch InBev NV https://www.fool.com/investing/2017/08/31/better-buy-philip-morris-international-inc-vs-anhe.aspx?source=iedfolrf0000001 Aug 31, 2017 - In a battle of sin stocks, we've got a draw. But each one's strength lies in a different area.
3 Reasons to Applaud Gilead Sciences' Acquisition of Kite Pharma https://www.fool.com/investing/2017/08/28/3-reasons-to-applaud-gilead-sciences-acquisition-o.aspx?source=iedfolrf0000001 Aug 28, 2017 - There's a lot to like with Gilead's buyout of cell therapy leader Kite Pharma.
Why Are Cancer Drugs So Expensive? https://www.fool.com/investing/2017/09/20/why-are-cancer-drugs-so-expensive.aspx?source=iedfolrf0000001 Sep 20, 2017 - If it seems like oncology drug prices are rapidly outpacing inflation, it’s because they are.
Teva Investors Get Headache Relief https://www.wsj.com/articles/teva-investors-get-headache-relief-1537200489?mod=rss_Technology Sep 17, 2018 - A new migraine drug is a big win amid the turnaround of generics business.
Why the Ionis Spinoff Will Be a Win for Long-Term Investors https://www.fool.com/investing/2017/04/18/why-the-ionis-spinoff-will-be-a-win-for-long-term.aspx?source=iedfolrf0000001 Apr 18, 2017 - Ionis keeps doing what it's good at: developing new drugs and setting up future revenue streams
Why Trivago NV Stock Plummeted Wednesday https://www.fool.com/investing/2017/09/06/why-trivago-nv-stock-plummeted-wednesday.aspx?source=iedfolrf0000001 Sep 06, 2017 - Trivago surprised investors this week when it lowered its outlook for 2017. Here are the details.
Why You're Smart to Buy Vertex Pharmaceuticals Stock https://www.fool.com/investing/2017/07/15/why-youre-smart-to-buy-vertex-pharmaceuticals-stoc.aspx?source=iedfolrf0000001 Jul 15, 2017 - Forget the sky-high valuation. Vertex Pharmaceuticals stock is a smart pick.
Is the System Rigged Against Biosimilars? https://www.fool.com/investing/2017/08/26/is-the-system-rigged-against-biosimilars.aspx?source=iedfolrf0000001 Aug 26, 2017 - Pfizer and Amgen are encountering problems getting traction for their biosimilars. Is the system rigged against them?
Why Juno Therapeutics Shares Vaulted 46% Higher in August https://www.fool.com/investing/2017/09/05/why-juno-therapeutics-shares-vaulted-46-higher-in.aspx?source=iedfolrf0000001 Sep 05, 2017 - Optimism is soaring following the FDA approval of Novartis' CAR-T and the $11.9 billion acquisition of CAR-T developer Kite Pharma.
Stocks making the biggest move premarket: UTX, AAPL, HIBB, NVS, TSLA & more https://www.cnbc.com/2018/11/27/stocks-making-the-biggest-move-premarket-utx-aapl-hibb-nvs-tsla--more.html Nov 27, 2018 - Names on the move ahead of the open.

Pages: 1234567...145

<Page 2>